Exemestane Side Effects and Management
Common Side Effects
- Hot flashes occur in 13% of patients and represent the most common endocrine symptom 1, 4
- Fatigue affects approximately 8-22% of patients 1, 4
- Increased sweating occurs in 4-6% of patients 1, 4
- Insomnia is a statistically significant adverse event 1, 2, 3
- Nausea affects 9-18% of patients 1, 4
- Diarrhea is statistically more common than placebo 1, 2, 3
- Joint and muscle pain (arthralgia/myalgia) represents a statistically significant adverse event that is characteristic of aromatase inhibitors 1, 2, 3, 5, 6
- Vasomotor symptoms are statistically increased 1, 3, 7
- Bodily pain is significantly increased compared to placebo 1, 3, 7
- Sexual problems occur more frequently than with placebo 1, 3, 7
Serious Adverse Events
- No statistically significant difference in cardiovascular events compared to placebo (106 events with exemestane vs. 111 with placebo, P=0.78) 2, 4
- Stroke rates are similar (13 with exemestane vs. 11 with placebo) 2, 4
- No treatment-related deaths were observed 1, 3, 8, 7
- No statistically significant increase in skeletal fractures (149 with exemestane vs. 143 with placebo, P=0.72) 1, 2, 4, 9
- Endometrial cancer rates are not significantly different (5 with exemestane vs. 8 with placebo) 2, 4
- No increase in other malignancies 1, 3
Bone Health Concerns
- Statistically significant reduction in bone mineral density at multiple sites: distal tibia, distal radius, lumbar spine, total hip, and femoral neck 1, 2, 3, 8, 7
- Cortical thickness is reduced at distal tibia and distal radius 1, 2, 3
- Bone loss occurs despite calcium and vitamin D supplementation 1, 2, 3, 8, 7
- Two years of treatment worsens age-related bone loss in postmenopausal women 1, 2, 3
Clinical Management
- Bone monitoring is mandatory during exemestane treatment 1, 3, 8, 7
- Adequate vitamin D and calcium supplementation is required 1, 2, 3, 8, 7
- The American Society of Clinical Oncology (ASCO) guideline emphasizes that "the potential for bone loss should be mentioned when discussing the risks and benefits of exemestane" 1, 3, 8